Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (105)

2024

  1. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  2. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  3. Melanoma Registry of the Spanish Academy of Dermatology and Venereology (REGESMEL): Description and Data in its First Year of Operation

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 663-669

  4. Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: Results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery)

    Journal of the European Academy of Dermatology and Venereology

  5. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  6. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

    Surgical Oncology, Vol. 52

  7. Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

    BMC Cancer, Vol. 24, Núm. 1

  8. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  9. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology

  10. Status of head and neck brachytherapy in Spain in 2022

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460

  11. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

  12. Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort

    Radiotherapy and Oncology, Vol. 194

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 8, pp. 1587-1594

  3. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

  4. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

  5. Interventional Radiotherapy (Brachytherapy) for the Treatment of Primary Lesions in Nasal Vestibule Malignancies

    Malignancies of the Nasal Vestibule: A New Perspective on Classification, Staging, and Treatment (Springer International Publishing), pp. 135-144

  6. Prognostic factors for satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: A multicentric cohort study

    Journal of the American Academy of Dermatology, Vol. 89, Núm. 1, pp. 119-127

  7. Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer

    World Journal of Men's Health

  8. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570